Therapies modulating insulin resistance in Parkinson’s disease: A cross talk

Sharma, Tanya; Kaur, Darshpreet; Grewal, Amarjot Kaur; Singh, Thakur Gurjeet

doi:10.1016/j.neulet.2021.135754

Cited by 28 publications

(26 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, due to COVID-19, PD’s non-motor and motor symptoms will aggravate significantly (Bloem et al 2021 ). It is very well known that the typical non-motor characteristics of PD are ageusia and anosmia (Sharma et al 2021a , b ). Therefore, during COVID-19, the episode of hypogeusia and hyposmia could be a slight “hit” for the potential development of PD symptoms (Boika 2020 ).…”

Section: Covid-19 and Parkinson’s Diseasementioning

confidence: 99%

Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination

Kaur

Singh

et al. 2022

Inflammopharmacol

Self Cite

View full text Add to dashboard Cite

A novel coronavirus disease (COVID-19), caused by a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was discovered in Wuhan, China, in December 2019, and the world has suffered from a pandemic. As of 22nd March 2020, at least 185 countries worldwide had been affected by COVID-19. SARS-CoV-2, leading to COVID-19 pneumonia, infects cells through ACE-2 receptors. The disease has different clinical signs and symptoms, including chills, high fever, dyspnea, and cough. Other symptoms including haemoptysis, myalgia, diarrhoea, expectoration, and fatigue may also occur. The rapid rise in confirmation cases is severe in preventing and controlling COVID-19. In this review, the article will explore and evaluate the insights into how COVID influences patients with other comorbid conditions such as cardiovascular disease, diabetes, Parkinson’s, and how conditions Urolithiasis, anosmia, and anuria may develop after infection. The virus mutates and the variants are now prevalent in the present scenario where the world stands in eradicating the pandemic by looking into the development of vaccines by several countries and how the vaccination can temporarily help prevent COVID spread.

show abstract

Section: Covid-19 and Parkinson’s Diseasementioning

confidence: 99%

Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination

Kaur

Singh

et al. 2022

Inflammopharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Zhang et al, 2021). Excitingly, several studies have revealed the existence of an association between T2DM and PD (Fiory et al, 2019; Sharma et al, 2021). While epidemiological links between both diseases have been deeply described, the underlying pathways and common mechanisms remain still unresolved (Cheong et al, 2020).…”

Section: Resultsmentioning

confidence: 99%

“…Given the growing evidence of the relationship between PD and T2DM, antidiabetic drugs are being considered as promising PD therapies (Hassan et al, 2020; Renaud et al, 2018; Sharma et al, 2021). Interestingly, a pilot screen carried out by our group in DJ-1β mutant flies identified metformin as a candidate therapeutic compound for PD, being able to suppress motor defects in PD model flies (Sanz et al, 2017).…”

Section: Resultsmentioning

confidence: 99%

“…In particular, most of them demonstrated that T2DM is a risk factor of developing PD, and could worsen cognition in PD patients (Hassan et al, 2020). Accordingly, an increase in ISP activity was reported to improve motor and cognitive abilities, and to exert neuroprotective effects in PD patients (Sharma et al, 2021). Besides, alterations found in chronic T2DM patients, like microvascular complications, may lead to nephropathy, retinopathy and neuropathy (Álvarez-Rendón et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

“…T1DM is due to the autoimmune loss of pancreatic β-cells, whereas T2DM is caused by the appearance of insulin resistance and a progressive decrease of insulin production in β-cells (American Diabetes Association, 2013; Hassan et al, 2020). Interestingly, there is growing evidence that an important link between PD and T2DM does exist (Fiory et al, 2019; Sharma et al, 2021). In fact, T2DM and PD share characteristic phenotypes such as mitochondrial dysfunction, increased OS levels, inflammation and ER stress, which eventually might lead to the activation of the apoptotic pathway (Hassan et al, 2020; Rocha et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Exploring the link between Parkinson’s disease and Diabetes Mellitus in Drosophila

Sanz

Solana-Manrique

Lilao-Garzón

et al. 2022

Preprint

View full text Add to dashboard Cite

Parkinson's disease (PD) is the second most common neurodegenerative disease. Diabetes mellitus (DM) is a metabolic disease characterized by high levels of glucose in blood. Recent epidemiological studies are highlighting the link between both diseases; it is even considered that DM might be a risk factor for PD. To further investigate the likely relation of these diseases, we have used a Drosophila PD model based on inactivation of the DJ-1β gene (ortholog of human DJ-1), and diet-induced Drosophila and mouse T2DM models, together with human neuron-like cells. T2DM models were obtained by feeding flies with a high sugar containing medium, and mice with a high fat diet. Our results showed that both fly models exhibit common phenotypes such as alterations in carbohydrate homeostasis, mitochondrial dysfunction or motor defects, among others. In addition, we demonstrated that T2DM might be a risk factor of developing PD since our diet-induced fly and mouse T2DM models present DA neurodegeneration, a hallmark of PD. We have also confirmed that neurodegeneration is caused by increased glucose levels, which has detrimental effects in human neuron-like cells by triggering apoptosis and leading to cell death. Besides, the observed phenotypes were exacerbated in DJ-1β mutants cultured in the high sugared medium, indicating that DJ-1 might have a role in carbohydrate homeostasis. Finally, we have confirmed that metformin, an antidiabetic drug, is a potential candidate for PD treatment and that it could prevent PD onset in T2DM model flies. This result supports antidiabetic drugs as promising PD therapeutics.

show abstract

Evaluation of type 1 diabetes mellitus as a risk factor of Parkinson's disease in a Drosophila model

et al. 2023

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic metabolic disease characterized by high blood glucose levels, resulting from insulin dysregulation. Parkinson's disease (PD) is the most common neurodegenerative motor disorder caused by the selective loss of dopaminergic (DA) neurons in the substantia nigra pars compacta. DM and PD are both age‐associated diseases that are turning into epidemics worldwide. Previous studies have indicated that type 2 DM might be a risk factor of developing PD. However, scarce information about the link between type 1 DM (T1DM) and PD does exist. In this work, we have generated a Drosophila model of T1DM based on insulin deficiency to evaluate if T1DM could be a risk factor to trigger PD onset. As expected, model flies exhibited T1DM‐related phenotypes such as insulin deficiency, increased content of carbohydrates and glycogen, and reduced activity of insulin signaling. Interestingly, our results also demonstrated that T1DM model flies presented locomotor defects as well as reduced levels of tyrosine hydroxylase (a marker of DA neurons) in brains, which are typical PD‐related phenotypes. In addition, T1DM model flies showed elevated oxidative stress levels, which could be causative of DA neurodegeneration. Therefore, our results indicate that T1DM might be a risk factor of developing PD, and encourage further studies to shed light into the exact link between both diseases.

show abstract

Therapies modulating insulin resistance in Parkinson’s disease: A cross talk

Cited by 28 publications

References 68 publications

Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination

Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination

Exploring the link between Parkinson’s disease and Diabetes Mellitus in Drosophila

Evaluation of type 1 diabetes mellitus as a risk factor of Parkinson's disease in a Drosophila model

Contact Info

Product

Resources

About